Cytosorbents (CTSO) Fireside Chat summary

Introduction and agenda

• The discussion focused on the company's progress, regulatory strategy, financial outlook, and future opportunities, with a particular emphasis on the DrugSorb-ATR product and its U.S. approval pathway.

Background and experience of the speaker

• Dr. Chan is a Yale-trained physician with a Harvard residency in internal medicine, bringing deep clinical and management expertise.

• The CFO, Pete Mariani, has significant experience in managing financial challenges in the biotech sector.

Current industry trends

• Blood purification technologies are gaining traction for treating critical illnesses and perioperative bleeding, with increasing regulatory attention and unmet needs in cardiac surgery.

• There is a growing demand for solutions to manage blood thinners in surgical patients, as current reversal agents have significant risks.